Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-22-005231
Filing Date
2022-03-31
Accepted
2022-03-31 16:45:54
Documents
13
Period of Report
2022-03-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A axsm-20220325.htm   iXBRL 8-K/A 55967
2 EX-99.1 axsm-ex99_1.htm EX-99.1 911293
  Complete submission text file 0000950170-22-005231.txt   1186628

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20220325_lab.xml EX-101.LAB 13316
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20220325_pre.xml EX-101.PRE 9816
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20220325.xsd EX-101.SCH 2469
7 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20220325_htm.xml XML 5162
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37635 | Film No.: 22793487
SIC: 2834 Pharmaceutical Preparations